钙蛋白酶参与tau蛋白过度磷酸化和截断的机制研究进展

doi:10.3969/j.issn.1006-9771.2020.10.010

Abstract

Abstract:

Alzheimer's disease (AD) is one of the most common neurodegenerative diseases, which is characterized by cognitive and memory dysfunction. Calpain is widely activated in cells. Disturbance of calpain is currently thought to a main cause of hyperphosphorylation and abnormal cleavage of tau protein in AD pathology. Calpain affects the activities of glycogen synthase kinase 3 and protein phosphatase 2A, which causes abnormal hyperphosphorylation of multiple sites of tau protein, and mediates truncation of tau protein monomers, and induces neurodegeneration. Calpain is expected to be a potential target for drug therapy of AD.

Key words: calpain, Alzheimer's disease, tau protein, hyperphosphorylation, cleavage, review

CLC Number:

R749.16

GUO Kai-wen,YANG Cui-cui,ZHANG Lan. Advance in Mechanisms of Calpain Involved in Hyperphosphorylation and Truncation of Tau Protein (review)[J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2020, 26(10): 1182-1185.

References 44

[1]	Melissa E M, Val J L, Neill R G, et al. Clinicopathologic and ¹¹C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum[J]. Brain, 2015, 138(Pt 5):1370-1381. doi: 10.1093/brain/awv050 pmid: 25805643
[2]	Zhao X, Kotilinek L A, Smith B, et al. Caspase-2 cleavage of tau reversibly impairs memory[J]. Nat Med, 2016, 22(11):1268-1276. doi: 10.1038/nm.4199
[3]	Afreen S, Riherd Methner D N, Ferreira A. Tau_45-230 association with the cytoskeleton and membrane-bound organelles: functional implications in neurodegeneration[J]. Neuroscience, 2017, 362:104-117. doi: S0306-4522(17)30592-4 pmid: 28844006
[4]	Quinn J P, Corbett N J, Kellett K, et al. Tau proteolysis in the pathogenesis of tauopathies: neurotoxic fragments and novel biomarkers[J]. J Alzheimers Dis, 2018, 63(1):13-33. doi: 10.3233/JAD-170959
[5]	Lang A E, Riherd Methner D N, Ferreira A. Neuronal degeneration, synaptic defects, and behavioral abnormalities in tau_45-230 transgenic mice[J]. Neuroscience, 2014, 275:322-339. doi: 10.1016/j.neuroscience.2014.06.017 pmid: 24952329
[6]	Reith Maarten E A. Handbook of Neurochemistry and molecular neurobiology 2007: neural membranes and transport[J]. Springer, 2007: 3-16.
[7]	Zhu L, Gong L, Yang T, et al. Calpastatin mediates development of Alzheimer's disease in diabetes[J]. J Alzheimers Dis, 2019, 68(3):1051-1059. doi: 10.3233/JAD-190004
[8]	Mahaman Y A R, Huang F, Kessete Afewerky H, et al. Involvement of calpain in the neuropathogenesis of Alzheimer's disease[J]. Med Res Rev, 2019, 39(2):608-630. doi: 10.1002/med.2019.39.issue-2
[9]	Siklos M, Benaissa M, Thatcher G R. Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors[J]. Acta Pharm Sin B, 2015, 5(6):506-519. doi: 10.1016/j.apsb.2015.08.001
[10]	Yamashima T. Reconsider Alzheimer's disease by the 'calpain-cathepsin hypojournal': a perspective review[J]. Prog Neurobiol, 2013, 105:1-23. doi: 10.1016/j.pneurobio.2013.02.004
[11]	朱家佳, 龙鼎新. 钙蛋白酶研究进展[J]. 生命的化学, 2017, 37(6):958-963.
	Zhu J J, Long D X. The research progress of calpain[J]. Chem Life, 2017, 37(6):958-963.
[12]	齐曾鑫, 蔡加君, 瑜姚, 等. 钙蛋白酶的研究进展[J]. 中国临床神经科学, 2013, 21(4):456-462.
	Qi Z X, Cai J J, Yu Y, et al. Progress on study of calpain[J]. Chin J Clin Neurosci, 2013, 21(4):456-462.
[13]	Bevers M B, Neumar R W. Mechanistic role of calpains in postischemic neurodegeneration[J]. J Cereb Blood Flow Metab, 2008, 28(4):655-673. doi: 10.1038/sj.jcbfm.9600595
[14]	Goll D E, Thompson V F, Li H, et al. The calpain system[J]. Physiol Rev, 2003, 83(3):731-801. doi: 10.1152/physrev.00029.2002
[15]	Yamashima T. Can 'calpain-cathepsin hypojournal' explain Alzheimer neuronal death?[J]. Ageing Res Rev, 2016, 32:169-179. doi: 10.1016/j.arr.2016.05.008
[16]	Zatz M, Starling A. Calpains and disease[J]. N Engl J Med, 2005, 23(352):2413-2423.
[17]	Arthur J S, Elce J S, Hegadorn C, et al. Disruption of the murine calpain small subunit gene, capn4: calpain is essential for embryonic development but not for cell growth and division[J]. Mol Cell Biol, 2000, 20(12):4474-4481. pmid: 10825211
[18]	Ohno S, Emori Y, Imajoh S, et al. Evolutionary origin of a calcium-dependent protease by fusion of genes for a thiol protease and a calcium-binding protein[J]. Nature, 1984, 312(5994):566-570. pmid: 6095110
[19]	Storr S J, Thompson N, Pu X, et al. Calpain in breast cancer: role in disease progression and treatment response[J]. Pathobiology, 2015, 82(3-4):133-141. doi: 10.1159/000430464
[20]	Moldoveanu T, Hosfield C M, Lim D, et al. A Ca(2+) switch aligns the active site of calpain[J]. Cell, 2002, 108(5):649-660. pmid: 11893336
[21]	Ono Y, Sorimachi H. Calpains: an elaborate proteolytic system[J]. Biochim Biophys Acta, 2012, 1824(1):224-236.
[22]	Reverter D, Sorimachi H, Bode W. The structure of calcium-free human m-calpain: implications for calcium activation and function[J]. Trends Cardiovasc Med, 2001, 11(6):222-229. doi: 10.1016/S1050-1738(01)00112-8
[23]	Higuchi M, Iwata N, Matsuba Y, et al. Mechanistic involvement of the calpain-calpastatin system in Alzheimer neuropathology[J]. FASEB J, 2012, 26(3):1204-1217. doi: 10.1096/fj.11-187740 pmid: 22173972
[24]	Patzke H, Tsai L H. Calpain-mediated cleavage of the cyclin-dependent kinase-5 activator p39 to p29[J]. J Biol Chem, 2002, 277(10):8054-8060. doi: 10.1074/jbc.M109645200
[25]	Rao M V, Mohan P S, Peterhoff C M, et al. Marked calpastatin (CAST) depletion in Alzheimer's disease accelerates cytoskeleton disruption and neurodegeneration: neuroprotection by CAST overexpression[J]. J Neurosci, 2008, 28(47):12241-12254. doi: 10.1523/JNEUROSCI.4119-08.2008
[26]	Cortés N, Andrade V, Guzmán-Martínez L, et al. Neuroimmune tau mechanisms: their role in the progression of neuronal degeneration[J]. Int J Mol Sci, 2018, 19(4):956. doi: 10.3390/ijms19040956
[27]	Jin N, Wu Y, Xu W, et al. C-terminal truncation of GSK-3β enhances its dephosphorylation by PP2A[J]. FEBS Lett, 2017, 591(7):1053-1063. doi: 10.1002/1873-3468.12617
[28]	Hu Y, Ruan W, Gao A, et al. Synjournal and biological evaluation of novel 4,5-bisindolyl-1,2,4-triazol-3-ones as glycogen synthase kinase-3β inhibitors and neuroprotective agents[J]. Pharmazie, 2017, 72(12):707-713.
[29]	Majd S, Majd Z, Koblar S, et al. Beta estradiol and norepinephrine treatment of differentiated SH-SY5Y cells enhances tau phosphorylation at (Ser 396 ) and (Ser 262 ) via AMPK but not mTOR signaling pathway[J]. Mol Cell Neurosci, 2018, 88:201-211. doi: 10.1016/j.mcn.2018.02.004
[30]	Chang W, Huang D, Martin Y L, et al. Protective effect of caffeic acid against Alzheimer's disease pathogenesis via modulating cerebral insulin signaling, β-amyloid accumulation, and synaptic plasticity in hyperinsulinemic rats[J]. J Agric Food Chem, 2019, 67(27):7684-7693. doi: 10.1021/acs.jafc.9b02078
[31]	Huang J, Huang F, Yang C. Moscatilin ameliorates tau phosphorylation and cognitive deficits in Alzheimer's disease models[J]. J Nat Prod, 2019, 82(7):1979-1988. doi: 10.1021/acs.jnatprod.9b00375
[32]	Yao Y, Wang Y, Kong L, et al. Osthole decreases tau protein phosphorylation via PI3K/AKT/GSK-3β signaling pathway in Alzheimer's disease[J]. Life Sci, 2019, 217:16-24. doi: 10.1016/j.lfs.2018.11.038
[33]	Chen J, Long Z, Li Y, et al. Alteration of the Wnt/GSK3β/β‑catenin signalling pathway by rapamycin ameliorates pathology in an Alzheimer's disease model[J]. Int J Mol Med, 2019, 44(1):313-323.
[34]	Goñi-Oliver P, Lucas J J, Avila J, et al. N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation[J]. J Biol Chem, 2007, 282(31):22406-22413. pmid: 17569662
[35]	Aweida D, Rudesky I, Volodin A, et al. GSK3-beta promotes calpain-1-mediated desmin filament depolymerization and myofibril loss in atrophy[J]. J Cell Biol, 2018, 217(10):3698-3714. doi: 10.1083/jcb.201802018
[36]	Thornton T M, Hare B, Colie S, et al. Failure to inactivate nuclear GSK3β by Ser389-phosphorylation leads to focal neuronal death and prolonged fear response[J]. Neuropsychopharmacology, 2018, 43(2):393-405. doi: 10.1038/npp.2017.187
[37]	Iqbal K, Gong C, Liu F. Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease[J]. Expert Opin Ther Targets, 2014, 18(3):307-318. doi: 10.1517/14728222.2014.870156
[38]	Sontag J M, Sontag E. Protein phosphatase 2A dysfunction in Alzheimer's disease[J]. Front Mol Neurosci, 2014, 7:16.
[39]	Bertoli C, Copetti T, Lam E W, et al. Calpain small-1 modulates Akt FoxO3A signaling and apoptosis through PP2A[J]. Oncogene, 2009, 28(5):721-733. doi: 10.1038/onc.2008.425 pmid: 19029949
[40]	Ma X H, Duan W J, Mo Y S, et al. Neuroprotective effect of paeoniflorin on okadaic acid-induced tau hyperphosphorylation via calpain/Akt/GSK-3β pathway in SH-SY5Y cells[J]. Brain Res, 2018, 1690:1-11. doi: 10.1016/j.brainres.2018.03.022
[41]	Zhu G, Briz V, Seinfeld J, et al. Calpain-1 deletion impairs mGluR-dependent LTD and fear memory extinction[J]. Sci Rep, 2017, 7:42788. doi: 10.1038/srep42788
[42]	Janssens V, Derua R, Zwaenepoel K, et al. Specific regulation of protein phosphatase 2A PR72/B′′ subunits by calpain[J]. Biochem Biophys Res Commun, 2009, 386(4):676-681.
[43]	Chen H H, Liu P, Auger P, et al. Calpain-mediated tau fragmentation is altered in Alzheimer's disease progression[J]. Sci Rep, 2018, 8(1):16725. doi: 10.1038/s41598-018-35130-y
[44]	Manassero G, Guglielmotto M, Monteleone D, et al. Dual mechanism of toxicity for extracellular injection of tau oligomers versus monomers in human tau mice[J]. J Alzheimers Dis, 2017, 59(2):743-751. doi: 10.3233/JAD-170298 pmid: 28671129

Advance in Mechanisms of Calpain Involved in Hyperphosphorylation and Truncation of Tau Protein (review)

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 44

Related Articles 15

Metrics

Comments

Recommended 0

[1]	SHAO Weiting, LEI Jianghua. Effect of response interruption and redirection as a behavioral intervention on vocal stereotypy in children with autism spectrum disorder: a scoping review [J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2024, 30(1): 10-20.
[2]	WANG Hangyu, GE Keke, FAN Yonghong, DU Lilu, ZOU Min, FENG Lei. Effect of active music therapy on cognitive function for older adults with cognitive impairment: a systematic review based on ICD-11 and ICF [J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2024, 30(1): 36-43.
[3]	WEN Jianing, JIN Qiuyan, ZHANG Qi, LI Jie, SI Qi. Effect of cognitively engaging physical activity on developing executive function of children and adolescents: a systematic review based on ICF [J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2024, 30(1): 44-53.
[4]	GE Keke, FAN Yonghong, WANG Hangyu, DU Lilu, LI Changjiang, ZOU Min. Health benefit of mindfulness intervention for older adults with insomnia disorders: a systematic review [J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2024, 30(1): 54-60.
[5]	ZHANG Jingya, ZOU Min, SUN Hongwei, SUN Changlong, ZHU Juntong. Effect of psychological intervention on anxiety or depression in children and adolescents with hearing impairment: a systematic review [J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2023, 29(9): 1004-1011.
[6]	WANG Junyu, YANG Yong, YUAN Xun, XIE Ting, ZHUANG Jie. Effect of high-intensity interval training on executive function for healthy children and adolescents: a systematic review [J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2023, 29(9): 1012-1020.
[7]	WEI Xiaowei, YANG Jian, WEI Chunyan. Psychological and behavioral benefits of adapted yoga exercise for children with autism spectrum disorder in special education schools: a systematic review [J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2023, 29(9): 1021-1028.
[8]	YANG Yaru, YANG Jian. School-based physical activity-related health services and their health benefits within the World Health Organization health-promoting school framework: a systematic review of systematic reviews [J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2023, 29(9): 1040-1047.
[9]	WANG He, HAN Liang, KAN Mengfan, YU Shaohong. Efficacy of electrical stimulation on shoulder-hand syndrome after stroke: a systematic review and meta-analysis [J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2023, 29(9): 1048-1056.
[10]	SHI Jiawei, LI Lingyu, YANG Haojie, WANG Qinlu, ZOU Haiou. Effect of preoperative prerehabilitation training on total knee arthroplasty: a systematic review of systematic reviews [J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2023, 29(9): 1057-1064.
[11]	JIANG Changhao, HUANG Chen, GAO Xiaoyan, DAI Yuanfu, ZHAO Guoming. Effect of neurofeedback training on cognitive function in the elderly: a systematic review [J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2023, 29(8): 903-909.
[12]	WEI Xiaowei, YANG Jian, WEI Chunyan, HE Qiling. Adapted physical education programs for psychomotor development in school settings for children with intellectual and developmental disabilities: a systematic review [J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2023, 29(8): 910-918.
[13]	ZHANG Yuan, YANG Jian. School health services and effectiveness based on World Health Organization health-promoting school framework: a scoping review [J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2023, 29(7): 791-799.
[14]	WANG Shaopu, CHEN Gang. Psychological-behavioral health services and its outcome based on World Health Organization health-promoting school framework: a systematic review of systematic reviews [J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2023, 29(7): 800-807.
[15]	JIANG Changhao, GAO Xiaoyan. Effect of acute physical activity on cognitive function in children: a systematic review [J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2023, 29(6): 667-672.